Centers for Disease Control and Prevention,National Center for HIV Viral Hepatitis STD and TB Prevention

This information sheet discusses TB and the risk for international travelers. It explains TB transmission, multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of the disease, and how drug resistance occurs. The information sheet considers whether international travelers are at risk of MDR or XDR TB while traveling, the risk of acquiring TB on an airplane, how TB can be prevented, TB vaccine, and what an individual should do before traveling internationally and if an individual thinks that he/she may have been exposed to someone with TB disease.

This information sheet discusses TB and the risk for international travelers. It explains TB transmission, multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of the disease, and how drug resistance occurs. The information sheet considers whether international travelers are at risk of MDR or XDR TB while traveling, the risk of acquiring TB on an airplane, how TB can be prevented, TB vaccine, and what an individual should do before traveling internationally and if an individual thinks that he/she may have been exposed to someone with TB disease.

This information sheet explains TB for employers in non-healthcare settings. It describes TB disease, latent TB infection (LTBI), active TB, how it is determined whether a patient has active TB or LTBI, the symptoms of TB, what one should do if an employee reports having positive TB or has been in contact with someone with TB, and what happens after the employer contacts the local or state TB program.

This information sheet presents important facts about viral hepatitis A, B, and C. For all three hepatitis types, it provides information regarding vaccines, statistics, where the virus is found in the body, how it is spread, what happens when a person is infected, and public health strategies.

This information sheet discusses treatment for latent TB infection. It reminds patients to keep their weekly medical visits, explains directly observed therapy, provides a list of items to discuss with their doctor, a medication schedule, and advises them to call the doctor immediately if they experience any of the side effects on the list. The information sheet also includes space for the doctor's and clinic's name and telephone number.

This information sheet discusses multidrug-resistant TB (MDR TB), a strain of TB that is resistant to at least two of the best anti-TB drugs, isoniazid and rifampicin. It describes TB disease, MDR TB, extensively drug resistant TB (XDR TB), TB transmission, how drug resistance happens, and who is at risk for getting MDR TB. The information sheet also explains how MDR TB can be prevented, TB vaccine, the symptoms of TB disease, and what an individual should do after being exposed to someone with TB.

This document is intended for use as a reference manual for clinicians caring for persons with or at high risk for TB disease or infection. It is not meant to provide detailed answers to all public health or clinical questions about TB, and it is not meant as a substitute for any specific guidelines.

This information sheet discusses the once-a-week 12-week treatment of rifapentine and isoniazid for latent TB infection (LTBI). It explains LTBI, why it is necessary to treat it, the treatment plan and how it is managed, and a chart for tracking. It also includes hints on how to take the medicine including eating before taking it and avoiding alcohol, and describes normal side effects and possible problems including which signs and symptoms require you to call the doctor or nurse and what to do when taking a dose of medicine in the absence of medical staff.